Paradigm Therapeutics

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa	Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Skin Abnormalities, Skin and Connective Tissue Diseases, epidermolysis bullosa, hereditary disease, hereditary skin disorder, skin disorder, vesiculobullous skin disease	Not yet recruiting	Phase 3	2026-09-09		NCT07482813
Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa	Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Pathological Conditions, Signs and Symptoms, Pruritus, Signs and Symptoms, Skin Abnormalities, Skin Manifestations, Skin and Connective Tissue Diseases, epidermolysis bullosa, hereditary disease, hereditary skin disorder, skin disorder, vesiculobullous skin disease	Recruiting	Phase 3	2026-09-04		NCT07482787

Clinical trials